JCXH 105
Alternative Names: JCXH-105Latest Information Update: 05 Sep 2024
At a glance
- Originator Immorna
- Class RNA vaccines; Varicella vaccines
- Mechanism of Action Immunostimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Phase I Herpes zoster
Most Recent Events
- 03 Sep 2024 Immorna Biotherapeutics plans a phase II trial for Herpes zoster (Prevention, In adults, In the elderly) (IM, Injection) in September 2024 (NCT06581575)
- 25 Mar 2024 Immorna Biotherapeutics completes a phase-I clinical trial in Herpes zoster (Prevention) in USA (IM) (NCT05871541)
- 25 May 2023 Phase-I clinical trials in Herpes zoster (Prevention) in USA (IM) (Immorna pipeline; February 2023) (NCT05871541)